EUVIMEDOpdag EUVIMED
Open access

Diagnostic Value of CCL2 and CCR2 in Pleural Effusion for Distinguishing Lung Cancer Histological Subtypes: A Retrospective Study

Jie Yu iD, Yong Huang iD, Weirong Chen iD

Diagnostic Cytopathology · 2026

DOI: 10.1002/dc.70165 ↗

At a glance

Journal article in Diagnostic Cytopathology, 2026. Written by Jie Yu and 2 co-authors. Institution: Department of Thoracic Surgery, Nantong Haimen People's Hospital, Nantong, Jiangsu, China. Major MEDLINE topics: Receptors, CCR2, Chemokine CCL2, Lung Neoplasms, Biomarkers, Tumor. Cited 1 times so far (Crossref); 31 references. The full text is freely available in PubMed Central.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

This study evaluated the diagnostic value of C‐C motif chemokine ligand 2 (CCL2) and C‐C chemokine receptor type 2 (CCR2) in pleural effusions for distinguishing histological subtypes of lung cancer (LC).

Methods

A retrospective cohort study was conducted on 96 cases of squamous cell carcinoma (LUSC), 206 cases of lung adenocarcinoma (LUAD), and 53 cases of small cell LC (SCLC). A control group of 102 patients with parapneumonic effusion was selected. CCL2 and CCR2 levels in pleural effusions were measured. Pearson correlation analysis and receiver operating characteristic curve analysis were conducted.

Results

Pleural effusion CCL2 and CCR2 levels were higher in advanced LC than in parapneumonic effusion, and the changes in these two levels showed a moderate positive correlation ( p < 0.001). CCL2 and CCR2 levels in pleural effusions were elevated in LUAD patients compared to LUSC and SCLC patients ( p < 0.01), with SCLC patients having higher levels than LUSC patients ( p < 0.01). The AUC for the combined CCL2 and CCR2 panel was higher than that for CCL2, CCR2, carcinoembryonic antigen, and cytokeratin fragment antigen 21‐1 tested individually (all p < 0.05).

Conclusion

Patients with advanced LC exhibit elevated CCL2 and CCR2 levels in pleural effusions. Combined detection of these two markers has some diagnostic value in distinguishing between LUAD and LUSC, serving as a valuable supplement to histopathological examination; however, clinical application should involve a comprehensive assessment in conjunction with other auxiliary tests. These markers have limited value in distinguishing between SCLC and NSCLC.

Subjects

MeSH terms (MEDLINE)

Receptors, CCR2Chemokine CCL2Lung NeoplasmsBiomarkers, TumorPleural Effusion, MalignantCarcinoma, Squamous CellSmall Cell Lung CarcinomaHumansFemaleRetrospective StudiesMaleMiddle AgedAgedDiagnosis, DifferentialAdult

Author keywords

CCL2CCR2differential diagnosishistological typelung cancerpleural effusions

Substances

Receptors, CCR2Chemokine CCL2CCR2 protein, humanCCL2 protein, humanBiomarkers, Tumor

Authors and institutions

  • Department of Thoracic Surgery, Nantong Haimen People's Hospital, Nantong, Jiangsu, China.

ORCID profiles: Jie Yu, Yong Huang, Weirong Chen

Cite

APA

Yu, J., Huang, Y., & Chen, W. (2026). Diagnostic Value of CCL2 and CCR2 in Pleural Effusion for Distinguishing Lung Cancer Histological Subtypes: A Retrospective Study. Diagnostic Cytopathology. https://doi.org/10.1002/dc.70165

Vancouver

Yu J, Huang Y, Chen W. Diagnostic Value of CCL2 and CCR2 in Pleural Effusion for Distinguishing Lung Cancer Histological Subtypes: A Retrospective Study. Diagnostic Cytopathology. 2026. doi:10.1002/dc.70165

BibTeX
@article{Yu2026,
  author = {Yu, Jie and Huang, Yong and Chen, Weirong},
  title = {Diagnostic Value of CCL2 and CCR2 in Pleural Effusion for Distinguishing Lung Cancer Histological Subtypes: A Retrospective Study},
  journal = {Diagnostic Cytopathology},
  year = {2026},
  doi = {10.1002/dc.70165}
}
Start for free →